Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells
| Autor: | DeWitt, Mark A, Magis, Wendy, Bray, Nicolas L, Wang, Tianjiao, Berman, Jennifer R, Urbinati, Fabrizia, Heo, Seok-Jin, Mitros, Therese, Muñoz, Denise P, Boffelli, Dario, Kohn, Donald B, Walters, Mark C, Carroll, Dana, Martin, David IK, Corn, Jacob E |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Biomedical Knockout SCID Regenerative Medicine Medical and Health Sciences Cell Line Sickle Mice Rare Diseases Stem Cell Research - Nonembryonic - Human Translational Research Genetics Animals Humans Hemoglobin Polymorphism Translational Medical Research Gene Editing Transplantation Sickle Cell Disease Pain Research Human Genome Anemia Single Nucleotide Hematology Biological Sciences Hematopoietic Stem Cells Stem Cell Research Sickle Cell Adult Stem Cells Blood Mutation Inbred NOD Heterografts CRISPR-Cas Systems Biotechnology |
| Zdroj: | Science translational medicine, vol 8, iss 360 |
| Popis: | Genetic diseases of blood cells are prime candidates for treatment through ex vivo gene editing of CD34+ hematopoietic stem/progenitor cells (HSPCs), and a variety of technologies have been proposed to treat these disorders. Sickle cell disease (SCD) is a recessive genetic disorder caused by a single-nucleotide polymorphism in the β-globin gene (HBB). Sickle hemoglobin damages erythrocytes, causing vasoocclusion, severe pain, progressive organ damage, and premature death. We optimize design and delivery parameters of a ribonucleoprotein (RNP) complex comprising Cas9 protein and unmodified single guide RNA, together with a single-stranded DNA oligonucleotide donor (ssODN), to enable efficient replacement of the SCD mutation in human HSPCs. Corrected HSPCs from SCD patients produced less sickle hemoglobin RNA and protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When engrafted into immunocompromised mice, ex vivo treated human HSPCs maintain SCD gene edits throughout 16 weeks at a level likely to have clinical benefit. These results demonstrate that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopoietic diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|